Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab dose frequency optimization in advanced NSCLC
NCT02713867Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started May 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02713867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713867.